Preliminary Results for the year ended 31 December 2022FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPSParsortix system substantially out-performs standard of care for ovarian cancer diagnosisProstate

Related Keywords

New Zealand , China , Zurich , Züsz , Switzerland , Austria , India , Czech Republic , Ukraine , Pennsylvania , United States , France , United Kingdom , Canada , Spain , Russia , Germany , Guildford , Surrey , London , City Of , Toronto , Ontario , Plymouth Meeting , Swiss , Andrew Newland , Milo Bonser , Shaam Vora , Toby Flaux , Garth Selvey , Ciaran Walsh , Ian Griffiths , Ciara Martin , Juliet Thompson , Simon Conway , Parsortix Ctcs , Thomas Bective , Joe Eid , Investor Centre , Company United States , Financial Conduct Authority , Molecular Oncology Laboratory , London Stock Exchange , Centers For Medicare , Interpretations International Financial Reporting Interpretation Committee , Surrey Research Park , Employee Share Ownership Trust , Medicaid Services , Swiss Federal Institute Of Technology , Solaris Health , Solaris Health Holdings , Midlantic Urology , Registrar Of Companies , Group Financial , Preliminary Results , Crescendo Biologics , Non Executive Directors , Non Executive Chairman , Joint Broker , Frequently Used Terms , Abuse Regulation , Swiss Federal Institute , Middle East , Lantic Urology , Financial Statements , Companies Act , Consolidated Financial Statements , Annual General , United Kingdom Adopted , Annual General Meeting , Holiday Inn Guildford , Egerton Road , London Stock , Primary Information Provider , Angle , Nnounces , Results , Ear , Nded , December , 022 ,